A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe Chronic Kidney Disease
Latest Information Update: 07 Jun 2024
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Renal failure
- Focus Therapeutic Use
- Acronyms The RENAL LIFECYCLE Trial
- 15 Nov 2022 Planned End Date changed from 1 Jan 2026 to 1 Jan 2027.
- 15 Nov 2022 Planned primary completion date changed from 1 Jan 2026 to 1 Jan 2027.
- 02 Aug 2022 Status changed from not yet recruiting to recruiting.